ATHERSYS, INC / NEW Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Gain from forgiveness of note payable
Depreciation and Amortization
Loss from impairment of assets
Compensation related to stock options
Discount on revenue from issuance of warrant
Other
Stock-based patent license and settlement expense
Gain from insurance proceeds, net
Operating right-of-use assets, net
Gain (loss) on sales of assets
Change in fair value of warrant liabilities

Changes in operating assets and liabilities:
Accounts receivable from Healios - billed and unbilled
Healios License Agreement
Healios
Consolidated entity, excluding related party
Total accounts receivable from Healios - billed and unbilled

Prepaid expenses, deposits and other
Accounts payable, accrued expenses and other
Consolidated entity, excluding related party
Total accounts payable, accrued expenses and other
Advances and deposits from Healios
Healios
Total advances and deposits from Healios
Deferred revenue - Healios
Healios License Agreement
Healios
Consolidated entity, excluding related party
Total deferred revenue - Healios

Deferred revenue
Accounts payable to Healios
Advance from Healios
Healios
Total advance from Healios

Net cash used in operating activities
Investing activities
Purchase of available-for-sale securities
Sales of available-for-sale securities
Proceeds from insurance, net
Proceeds from the sale of equipment
Purchases of equipment
Net cash used in investing activities

Financing activities
Proceeds from issuance of common stock, net of issuance cost
Healios License Agreement
Healios
Consolidated entity, excluding related party
Total proceeds from issuance of common stock, net of issuance cost

Proceeds from the issuance of common stock and warrants, net of issuance cost
Proceeds from the exercise of pre-funded warrants
Shares retained for withholding tax payments on stock-based awards
Net cash provided by financing activities
Increase (decrease) in cash and cash equivalents
(Decrease) Increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Non-cash investing activities:
Right-of-use assets obtained in exchange for lease liabilities

Comments